Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and D...
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
About this item
Full title
Author / Creator
Beaver, Julia A , Hazarika, Maitreyee , Mulkey, Flora , Mushti, Sirisha , Chen, Huanyu , He, Kun , Sridhara, Rajeshwari , Goldberg, Kirsten B , Chuk, Meredith K , Chi, Dow-Chung , Chang, Jennie , Barone, Amy , Balasubramaniam, Sanjeeve , Blumenthal, Gideon M , Keegan, Patricia , Pazdur, Richard and Theoret, Marc R
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Patients who receive immunotherapeutic drugs might develop an atypical response pattern, wherein they initially meet conventional response criteria for progressive disease but later have decreases in tumour burden. Such responses warrant further investigation into the potential benefits and risks for patients who continue immunotherapy beyond disea...
Alternative Titles
Full title
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1990852743
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1990852743
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(17)30846-X
